• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Gastroenterology

Development of a risk index for colorectal cancer screening

byMoises GallegosandSai Folmsbee
August 11, 2015
in Gastroenterology, Oncology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. From a cross sectional study, this derived index can obtain measures to stratify risk for advanced colorectal neoplasia.

Evidence Rating Level: 2 (Good)

Study Rundown: Colorectal cancer screening has been demonstrated to be both beneficial and cost-effective. The U.S. Preventive Services Task Force recommends several tests and approaches to screening, but overall inefficiency in these has led to high costs. This study sought to develop a decision-making index to risk stratify average-risk persons and distinguish those individuals that may be managed with less invasive testing. Using common risk factors, including age, sex, waist circumference, cigarette smoking, and family history, the study authors created a scoring model to categorize patients into very low, low, intermediate, and high risk strata. Using pathology reports and this classification system, the authors calculated that the majority of patients in the very low and low groups with advanced neoplasm could have been identified with sigmoidoscopy, with success likely increased if fecal blood testing was added, sparing the cost and invasiveness of colonoscopy. Strengths to the model include the use of 5 easily obtained screening factors and an even distribution across risk groups that is improved compared to previous models. Limitations include a high percentage of white patients (94%), a lack of comparison between less-invasive approaches, and an inability to distinguish between proximal and distal disease. Overall, this risk index may inform and improve future colorectal screening.

Click to read the study, published today in Annals of Internal Medicine

Relevant Reading: USPSTF Colorectal Cancer Screening

In-Depth [cross-sectional study]: A total of 4500 participants presenting for first screening colonoscopy were enrolled. Two-thirds of the study group were used as a derivation set and the remaining third as the validation group. Ideal formats for risk factors (i.e., cigarette smoking, history, body fat, age and sex) were determined using individual logistics regressions, and a multivariable regression model was created. The model was well-calibrated (p = 0.42) and demonstrated good discrimination (c-statistic = 0.72). A score of 0-13 was calculated as the sum of points given for age (0 if <55, 1 if 55-60, 2 if 60-65, 3 if 65-70, and 4 if >70 years), sex (0 if F, 1 if M), first-degree relative (1 if one or more), smoking history (0 if none, 2 if 0-30, 4 if >30 pack-years), and waist circumference (0 = small, 1 = medium, 2 = large). Risk groups were defined as very low (score 0), low (score 1-3), intermediate (score 4-6), and high (score > 6), and the risk of neoplasia was 1.92%, 4.88%, 9.93% and 24.9% in these strata, respectively. A total of 51/70 (73%; 95%CI 61-83%) of the advanced neoplasms in the derivation set in the very low and low groups, and 21/24 (87.5%; 95%CI 68%-97%) of the advanced neoplasms in the validation very low and low groups, would have been detected on sigmoidoscopy.

RELATED REPORTS

In topline phase 3 results, nomelcitinib improved PASI 90 and PGA 0/1 responses versus placebo in plaque psoriasis

Intraosseous cefuroxime (Ceftin) may improve tissue delivery compared to intravenous administration during total knee arthroplasty

Image: CC/Wiki

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

2 Minute Medicine Rewind August 3 – August 10, 2015

Next Post

Corticosteroids improve outcomes in treatment of community-acquired pneumonia

RelatedReports

Psoriasis collage: an elbow with raised scaly patches, a jar of thick cream, oat stalks and a light therapy panel
2MM Trial Briefs

In topline phase 3 results, nomelcitinib improved PASI 90 and PGA 0/1 responses versus placebo in plaque psoriasis

November 2, 2026
Osteoarthritis collage: an engraved knee joint with worn cartilage, walking shoes and a hot-water bottle
Infectious Disease

Intraosseous cefuroxime (Ceftin) may improve tissue delivery compared to intravenous administration during total knee arthroplasty

November 2, 2026
Migraine collage of a young woman resting with eyes closed beside a teal zigzag ribbon, a curtained window and water
Weekly Rewinds

2 Minute Medicine Rewind November 2, 2026

November 2, 2026
Mitral valve prolapse collage of an engraved heart with a parachute-like valve, a stethoscope and a calm woman
Cardiology

Early mitral valve surgery may improve long-term survival in asymptomatic severe mitral regurgitation

October 31, 2026
Next Post

Corticosteroids improve outcomes in treatment of community-acquired pneumonia

Etiology of pediatric bacteremia and empiric treatment time vary

Internet-based intervention on proper handwashing limits spread of respiratory tract infections [PRIMIT trial]

Variation noted across pre- and post-marketing studies for FDA approved devices

Variation noted across pre- and post-marketing studies for FDA approved devices

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • In topline phase 3 results, nomelcitinib improved PASI 90 and PGA 0/1 responses versus placebo in plaque psoriasis
  • Intraosseous cefuroxime (Ceftin) may improve tissue delivery compared to intravenous administration during total knee arthroplasty
  • 2 Minute Medicine Rewind November 2, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.